Get started

Pharmaceuticals

UPDATE You pay less for Clicks for NOW target still R340You pay less at Clicks but the price is going up so now is the best time to buy. We have an Inverse Head and Shoulders pattern form, as I mentioned earlier. the price broke up and is showing strong upside to come. We have other indicators confirming including: 7>21>200 RSI>50 Target R340.76 ABOUT THE COMPANY Clicks is a well-known South African retail pharmacy, health, and beauty chain. Clicks was founded in 1968 in Cape Town, South Africa, as a health and beauty retail store. Product Range: Clicks offers a wide range of products, including pharmaceuticals, over-the-counter medications, beauty products, skincare, haircare, personal care items, and more. Store Network: Clicks has a vast network of stores across South Africa, with locations in cities, suburbs, and shopping malls. Pharmacy Services: Many Clicks stores have an in-house pharmacy, providing prescription medications, advice from qualified pharmacists, and other pharmaceutical services. Private Label Products: Clicks has its own private-label brands for various products, offering customers affordable alternatives to well-known brands. Wellness Clinics: Some Clicks stores have wellness clinics that offer various healthcare services, including vaccinations, screenings, and family planning consultations. Beauty Services: Some larger Clicks stores offer beauty services such as nail bars and eyebrow threading, enhancing the shopping experience. Online Shopping: Clicks offers an online platform where customers can shop for a wide range of products and have them delivered to their homes. Rewards Program: The Clicks ClubCard loyalty program offers customers discounts, cashback rewards, and personalized offers based on their shopping habits. Parent Company: Clicks is part of the Clicks Group, which also owns other retail brands like Musica, The Body Shop, and UPD (United Pharmaceutical Distributors). HOW IT GOT ITS NAME The "Clicks" name was apparently derived from the sound that the founder, Jack Goldin, heard from a clicking stethoscope, embodying the health focus he wanted for the company. However, due to the existing legislation, the health focus was not immediately realized until later years.
JSE:CLSLong
by Timonrosso
Eye Spy a MultibaggerI was hesitant to publish this chart because the extreme upside it shows will likely be viewed as unrealistic. However, HROW recently decisively broke above its 4-year trend channel as business developments have been quite positive lately - particularly with IHEEZO. This is a rare setup where the fundamentals and technicals both align for a sharp move to the upside. Over the short-term HROW may retest the trend channel breakout around the $17 region. If it holds, which I expect, I believe we could reach a triple-digit share price in short-order, potentially within 18-months, which would be a 500%+ return from today's share price of $19.50. My personal price target is $150/share by end of year 2025.
NASDAQ:HROWLong
by TomDaSpankEngine
2
Axsome Therapeutics building momentum Axsome Therapeutics Inc (AXSM) I have been in this spot trade since $50.77. We are now at $72.93. I have much higher targets as you can see from the chart. This is a long term trade looking to hold for 12 – 24 months however feel that something is going to happen within 6 – 12 months based on the chart. - Forming pennant on chart and RSI. Potential for breakout. - Steadily increasing OBV (On Balance Volume) demonstrating continued interested in the trade. - Stochastic Momentum indicator (not included on chart is driving upwards on the weekly). - You can see the orange boxes which act as accumulation zones with double bottoms before the larger move occurs. - We are above the 200 week and using it as support and we are above the 200 day also using it as support so we have limited downside with strong support. This purchase has been helped me recognized that Pharma appear to companies perform much better when the general market is in decline. They appear to be inverse risk on but also make small advances during risk on periods. It’s a market that I am becoming increasingly interested in as a diversifier and value lock. Obviously this is a smaller pharma company with higher risk in the trade, however if I was Regeneron or Johnson and Johnson and I see Axsome’s patents, drug offerings and the general population they are targeting with depression, Alzheimer’s and fibromyalgia, seems like a no brainer to buy them out. Fundamentals: AXSM are a Small Bio-Pharma company with market cap of $3.17 Billon. In August 2022 Auvelity Anti-Depressants was FDA approved & is the only rapid-acting oral medicine for MDD with labelling describing statistically significant antidepressant efficacy by one week. AXSM received Breakthrough Therapy designation from the FDA for an Alzheimer's disease drug development and are at the NDA phase for developing a drug for acute treatment of migraine. AXSM are also developing a treatment for narcolepsy and separately for fibromyalgia. All in, AXSM's offerings are building momentum. They have developed the fastest acting anti-depressant drug and are bringing it to market, and have a four other drugs in development, all of which have a large patient base. The company would be ripe for a buyout.
NASDAQ:AXSMLong
by PukaCharts
Mersana Therapeutics: Enjoy!If it holds support, it'll take off and head towards the top end of the range. Check out the crazy Call Options volume for the 8/18 $7.5 Strike Price... over 23,000 for this little unknown Pharma company. Somebody knows something... don't you think? Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA. The listed name for MRSN is Mersana Therapeutics, Inc. Common Stock.
NASDAQ:MRSNLong
by Goontata84
Profits Over Patients: The Morally Complex Realm of Big PharmaThis strategy dissects the dual nature of big pharmaceutical firms like Johnson & Johnson, Pfizer, Moderna, and Merck & Co viewed through base Fibonacci Extension Clustering. Despite big pharma's significant contributions to healthcare, these firms have benefited from questionable practices, including price manipulation and exploiting addictions . Price manipulation is a notorious strategy where companies arbitrarily hike drug prices, often without any significant improvements in their efficacy. "Big Pharma" has faced backlash for allegedly contributing to the opioid crisis . By aggressively marketing highly addictive pain medications , they may have exacerbated a public health catastrophe, leading to thousands of deaths annually. Such practices illuminate the immoral landscape of the pharmaceutical industry. While these firms play a vital role in global healthcare, their business tactics often prioritize profits over patients, demanding a closer scrutiny of this sector's ethics. 1. Johnson & Johnson (JNJ): Around $440 billion 2. Pfizer Inc. (PFE): Around $240 billion 3. Moderna Inc. (MRNA): Around $110 billion 4. Merck & Co., Inc. (MRK): Around $200 billion TOTAL = 1 Trillion
NASDAQ:MRNA
by MichaelBsul
VRPX Biotechnology Penny Stock Post EarningsVRPX was on a downtrend from mid-February into a reversal the beginning of May. VRPX beat earnings up still has no cash flow which is very common in this subsector. VRPX is priced on the potential of future earnings. The short and long-moving averages ratio shows bullish momentum also shows strength with an upper Bollinger Band "walk". Price has climbed over the POC line so it is higher than the mean of the share price traded for the duration of the volume profile. I see this as a risky long setup expectant of a 40% profit based on the target of the YTD high in February.
NASDAQ:VRPXLong
by AwesomeAvani
MGRX Biotechonolgy IPO LONGMGRX a recent IPO produces a med for erectile dysfunction without FDA approval; They are basically selling a generic version of an approved medication and bypassing the patent protections and betting they will fly under the regulator radar apparatus. As might be expeted this recent nano-IPO is highlly volatile. Play with it only if you have the requisite skills to do so and only with risk capital. it does the marketing through direct to consumer telehealth services. >>>>>>>>>>>>>>>>>>See also the link below <<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<< On review and analysis on the 30 minute chart, the price action is squeezing down in a flat bottom triangle likely setting up a breakout upside. The RSI oscillator shows RSI crossing 50% from below. Volatility is compressing down inside the triangle for a squeeze set up. Targets are based on the supply and demand zones of the Luxalgo indicator. The first parget is the midline between the zones while the final target is just below the supply zone. As can be seen on the chart, the first target is about 100% upside while the final target is 200% upside. One of the position is closed at each target making the return 150% overall. Stop loss is below the demand zone. A stop loss is 15% yields an overall reward to risk ration of 10:1.
NASDAQ:MGRXLong
by AwesomeAvani
Adcock showing strong upside to R57.61 but with warningInv Head and Shoulders formed on Adcock and now the price is above the neckline showing upside to come. 7>21>200 RSI>50 Bullish CONCERNS: This is a very volatile, flimsy and illiquid stock compared to the Blue Chips. I call these unhealthy charts which seldom work well with breakout patterns. Maybe as a Weekly analysis or Monthly will show some more promising price action, but daily is dangerous by just looking at it. Target R57.61 ABOUT Adcock Ingram is a South African pharmaceutical company that was founded in 1891 by Thomas Adcock and Joseph Ingram. It has a market capitalization of over R9 billion (Hence Medium Cap company that I don't like to trade). Adcock Ingram is one of the top pharmaceutical companies in South Africa, with a strong focus on the manufacturing, marketing, and distribution of healthcare products. They are also known for their insulin and penicillin. It has a ton of products, including over-the-counter medicines, prescription medicines, and medical devices. Some brands which I'm sure you know and helped you through Covid and your sick days are: Corenza: A popular brand of cold and flu medication in South Africa, known for its effervescent tablets. Linctagon: A range of cough and cold medications that includes lozenges, syrups, and capsules. Compral: A well-known brand of pain relievers, including tablets and capsules. Probiflora: A range of probiotic supplements designed to support digestive health. Bioplus: A popular energy supplement that is available in a variety of formulations, including capsules and effervescent tablets. Panado: A brand of pain relievers that is commonly used to treat headaches, fever, and other common ailments. Sominex: A sleep aid medication that is used to treat insomnia and other sleep disorders. Adcock Ingram has a strong presence in the African market, with operations in over 10 countries on the continent.
JSE:AIPLong
by Timonrosso
Sanofi S.A. (SAN.pa) bearish scenario:The technical figure Channel Up can be found in the daily chart in the French company Sanofi S.A. (SAN.pa). Sanofi S.A. is a French multinational pharmaceutical and healthcare company. Sanofi engages in the research and development, manufacturing and marketing of pharmacological products, principally in the prescription market, but the firm also develops over-the-counter medications. The corporation covers seven major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis, and vaccines (it is the world's largest producer of the last through its subsidiary Sanofi Pasteur). The Channel Up broke through the support line on 24/01/2023. If the price holds below this level, you can have a possible bearish price movement with a forecast for the next 26 days towards 86.54 EUR. According to experts, your stop-loss order should be placed at 92.90 EUR if you decide to enter this position. French drugmaker Sanofi SA plans to launch a drug for rare bleeding disorder hemophilia A this year, Chief Executive Officer Paul Hudson told CNBC in an interview last week. The U.S. Food and Drug Administration last year accepted the marketing application for the therapy, which is being developed in collaboration with Swedish drugmaker Sobi, and is expected to decide on an approval status by Feb. 28. Hemophilia A is an inherited bleeding disorder in which the blood does not clot normally. About 400 babies are born with this condition every year, although the exact number of people affected is not known, according to government data. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
EURONEXT:SANShort
by legacyFXofficial
Technical analysis of AbbVie #ABBVHey traders, My weekly trade idea. The daily price is forming a textbook Cup&Handle formation. After the consolidation in the handle phase, the price is ready to go higher. The momentum will push the price and in my opinion, it is headed to test the all-time high in the 180$ area. The Relative Strength Index broke above its trend line and is moving upward to push the price. Furthermore, when we plot different standard deviations and volume profile, it becomes clear that there is a lot of support and volume right below current price levels! I would love to hear your thoughts as well. Cheers
NYSE:ABBVLong
by RickHardyPro
3
UNITED HEALTH Buy Opportunity for this quarterThe UnitedHealth Group (UNH) hit the Resistance Zone following our last (November 18) signal but as it failed to break through its top, it got rejected: By doing so, the price even broke below the Higher Lows trend-line and the Bullish Megaphone pattern, that were in effect since February 2021. This potentially signals a deceleration on its enormous and sustainable rise but not necessarily that it turns bearish. In order to do so, it needs a closing below the 1W MA100 (red trend-line). Right now with the price on the 0.382 Fibonacci level and the 1D RSI oversold at 30.000, it is on the very same spot it was on the June 17 2022 Low. See between the two fractals, the successive hits on the 1D MA200 (orange trend-line) and 1D MA50 (blue trend-line). As a result, we consider this a buy opportunity back to the bottom (551.00) of the Resistance Zone. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support me, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- You may also TELL ME 🙋‍♀️🙋‍♂️ in the comments section which symbol you want me to analyze next and on which time-frame. The one with the most posts will be published tomorrow! 👏🎁 ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:UNHLong
by TradingShot
2
KALA New Drug on the Street Hi Traders We can't say much here! As always history has shown us when a new drug goes on the market we have 3 scenarios: 1 we're going up (green path) 2 the medicine is not good we are going down (red path) 3 we don't know what the medicine is like until many people take it let's go sideways (purple path) with all that is happening at the moment we are following the first scenario the probabilities looks good, but we will see as soon as the index open. Traders, if you liked this idea or if you have your own opinion about it, write in the comments. don't forget to follow me for more news and updates. Thanks for reading!
NASDAQ:KALALong
by GP101